Autres langues Cereno Scientific AB

Actions

CRNO B

SE0008241558

Temps Différé Nasdaq Stockholm Autres places de cotation 13:18:04 04/06/2024			Varia. 5j.	Varia. 1 janv.
4,25 ^SEK	-0,28%		-3,14%	-7,10%

23/05	Cereno Scientific AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
02/05	Cereno Scientific AB (Publ) annonce la nomination des membres du comité de nomination en vue de l'assemblée générale annuelle 2025	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)	03/06
Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024	30/05
Cereno Scientific participating at BIO 2024, June 3-6, San Diego	28/05
Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)	23/05
Cereno Scientific AB Reports Earnings Results for the First Quarter Ended March 31, 2024	23/05
Cereno Scientific presents at ABGSC Investor Days, May 23	17/05
Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress	15/05
Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025	02/05
Cereno Scientific AB Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025	02/05
Report from Annual General Meeting 2024 of Cereno Scientific AB	16/04
Cereno Scientific AB Approves Election of New Directors	16/04
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate	11/04
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family	11/04
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment	10/04
Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014	10/04
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014	10/04
Cereno Scientific Receives Patent Expansion in Europe	09/04
Cereno Scientific announces extended patent protection in Europe for CS585 program	09/04
Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific	03/04
Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH	28/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cereno Scientific AB

Actions

CRNO B

SE0008241558

Autres langues

Filtres